January 9, 2015
In studies sponsored by the National Institute of Allergy and Infectious Disease (NIAID), Greffex’s GreFluVie vaccine proved to be highly effective in protecting animals against H5N1. Mice were immunized in a prime/boost schedule before being challenged with a lethal dose of the pandemic avian influenza virus. At the low dose of 3×108 genome equivalents, the vaccine proved to be highly effective when given by intramuscular, subcutaneous, and intranasal routes. Intramuscular injection resulted in a rate of survival of 100%.
September 4, 2014
In the summer of 2014, Greffex was asked by the National Institute of Allergy and Infectious Diseases (NIAID) for a sample of its vaccine for MERS-CoV so that it could run tests to evaluate the production of neutralizing antibodies.
On a very tight schedule (less than two months) Greffex produced, purified, and vaccinated animals with the GreMERSfi. Mice were immunized in a prime/boost schedule with a small dose (approx. 3×108 genome equivalents). A standard micro-neutralization assay was used to quantify the humoral immune responses. All of the animals raised significant levels of neutralizing antibodies. 75% of the animals presented with very high antibody titers in the range of 640 to more than 2,560 (the test limit). In light of these results, the NIAID has invited Greffex to request further trials under its sponsorship.
AURORA, Colorado, June 24, 2013
MERS-CoV: In one month Greffex builds an advanced vaccine against the Middle East Respiratory Syndrome coronavirus
A scant two months after creating the first comprehensive vaccine for H7N9 avian influenza, Greffex developed a vaccine to protect against the Middle East Respiratory Syndrome coronavirus (MERS-CoV.) The vaccine was readied in just four weeks after MERS-CoV had moved to the WHO’s “alert phase” that also includes the human bird flu viruses H5N1 and H7N9.
platform combines a flexible ‘plug-and-play’TM
design accommodating different antigens, such as the MERS-CoV major surface S protein gene, with shortened development times of less than one month.
For more information about Greffex and its GREVAXTM vaccines, please go to our website: www.greffex.com or contact John R. Price at email@example.com / 303-577-0400.
AURORA, Colorado, 5/1/13
BusinessWire | Greffex has completed the construction of the first comprehensive vaccine against the virulent strain of H7N9 avian influenza.
Greffex scientists have created the first comprehensive vaccine for H7N9 avian influenza.
For more information about the Greffex and its GREVAXTM vaccines, please go to our website: www.greffex.com or contact John R. Price at firstname.lastname@example.org / 303-577-0400.
Greffex, Inc. announces the closing of an equity bridge round of $2,500,000 in which the Company issued convertible preferred shares representing a common equity equivalent of approximately 1% of the Company’s common stock.